GlassScriptPhysician profile
Ann Shattuck
NPI 1417566936
$14,735.66
in general payments reported to CMS, 2019-2025
66 companies · $3,345 in 2025
The $3,345 reported for 2025 was more than what 97% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,660 · 2022: $2,961 · 2023: $2,998 · 2024: $2,773 · 2025: $3,345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,858 · Education: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,858.41 |
| Education | $256.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $1,110.04 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Novartis Pharmaceuticals Corporation | $1,095.45 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $1,063.21 | 2021-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $893.81 | 2021-2025 | Opdivo, Opdualag, Augtyro |
| Astrazeneca Pharmaceuticals LP | $855.04 | 2021-2025 | Calquence, Tagrisso, Lynparza |
| Incyte Corporation | $776.89 | 2021-2025 | Jakafi |
| Lilly USA, LLC | $571.69 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Genzyme Corporation | $440.62 | 2021-2024 | |
| Amgen INC. | $390.78 | 2021-2023 | Lumakras, Xgeva, Nplate |
| Daiichi Sankyo INC. | $377.39 | 2021-2025 | Datroway, Injectafer, Enhertu |
| Jazz Pharmaceuticals INC. | $371.64 | 2021-2025 | |
| Seagen INC. | $369.78 | 2021-2023 | Padcev, Tukysa, Adcetris |
| Pfizer INC. | $354.80 | 2021-2025 | |
| Janssen Biotech, INC. | $331.99 | 2023-2025 | Rybrevant, Darzalex, Erleada |
| Genentech USA, INC. | $326.21 | 2022-2025 | Tecentriq, Phesgo, Venclexta |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $303.20 | 2021-2025 | |
| Rigel Pharmaceuticals, INC. | $288.72 | 2021-2024 | Tavalisse, Rezlidhia |
| Takeda Pharmaceuticals U.S.A., INC. | $278.73 | 2021-2025 | Exkivity, Fruzaqla, Iclusig |
| Glaxosmithkline, LLC. | $264.52 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Aveo Pharmaceuticals, INC. | $250.44 | 2022-2025 | |
| Kite Pharma, INC. | $233.40 | 2023-2025 | Yescarta |
| Regeneron Healthcare Solutions, INC. | $231.73 | 2022-2025 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $216.93 | 2021-2023 | Imbruvica |
| Novocure INC. | $198.94 | 2021-2025 | Optune Lua (Novottf-200t) |
| Astellas Pharma US INC | $182.46 | 2021-2024 | Padcev |
| Stemline Therapeutics INC. | $171.51 | 2023-2025 | Orserdu, Elzonris |
| Taiho Oncology, INC. | $158.25 | 2021-2025 | |
| Exelixis INC. | $156.26 | 2023-2025 | Cabometyx |
| Eisai INC. | $144.44 | 2021-2024 | |
| Epizyme, INC. | $142.68 | 2021-2022 | |
| Sobi, INC | $132.94 | 2024-2025 | |
| Array Biopharma INC | $107.09 | 2021-2025 | Mektovi, Braftovi, Lorbrena |
| Gilead Sciences, INC. | $103.36 | 2021-2025 | Trodelvy |
| Beigene USA, INC. | $101.76 | 2023-2024 | Brukinsa |
| Sanofi-Aventis U.S. LLC | $99.95 | 2022 | |
| Karyopharm Therapeutics INC. | $96.79 | 2021-2025 | Xpovio |
| Acrotech Biopharma INC. | $94.74 | 2021-2025 | Beleodaq |
| Puma Biotechnology, INC. | $94.64 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.58 | 2022-2025 | |
| Morphosys, US INC. | $89.75 | 2021-2023 | Monjuvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.25 | 2021-2025 | |
| Deciphera Pharmaceuticals INC. | $78.94 | 2023-2025 | Qinlock, Tgct |
| Beone Medicines USA, INC. | $76.63 | 2025 | Brukinsa, Tevimbra |
| Adc Therapeutics America, INC. | $75.26 | 2023-2025 | |
| Tersera Therapeutics LLC | $68.36 | 2022-2025 | Xermelo |
| Adaptive Biotechnologies Corporation | $64.41 | 2024-2025 | Clonoseq |
| Alexion Pharmaceuticals, INC. | $62.77 | 2022-2024 | Ultomiris |
| Secura Bio, INC. | $56.24 | 2021 | |
| Cti Biopharma Corp. | $54.71 | 2022-2023 | Vonjo |
| Ipsen Biopharmaceuticals, INC | $54.33 | 2023-2025 | Onivyde, Somatuline Depot |
| Genmab U.S., INC. | $52.19 | 2023-2025 | Tivdak, Epkinly |
| Geron Corporation | $49.44 | 2025 | Rytelo |
| Mirati Therapeutics, INC. | $45.06 | 2023 | Krazati |
| Azurity Pharmaceuticals, INC. | $42.71 | 2025 | Danziten |
| Servier Pharmaceuticals LLC | $41.55 | 2024 | |
| G1 Therapeutics, INC. | $36.12 | 2023 | Cosela |
| Emd Serono, INC. | $34.91 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $34.52 | 2023 | Sylvant |
| Accord Healthcare, INC. | $33.27 | 2023 | |
| Tolmar, INC. | $28.50 | 2024 | |
| Fennec Pharmaceuticals, INC. | $24.46 | 2024 | Pedmark |
| Pharmacosmos Therapeutics INC. | $19.76 | 2025 | Monoferric |
| Apellis Pharmaceuticals, INC. | $16.28 | 2024 | Empaveli |
| Mylan Institutional INC. | $15.38 | 2021 | |
| Myovant Sciences INC. | $13.92 | 2021 | |
| Sumitomo Pharma America, INC. | $13.54 | 2024 | Orgovyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Shattuck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.